Trial Profile

CF102-222PC: A Phase 2 Open-Label Study of the Safety and Activity of Namodenoson in the Treatment of Advanced Pancreatic Adenocarcinoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Jun 2025 According to a Can-Fite Biopharma media release, Dr. Sari Fishman, Vice President of Business Development, will present an update on the Companys ongoing Phase IIa study in pancreatic cancer during partnering meetings at the 2025 BIO International Convention, 50% of the planned patient cohort has already been enrolled and that Namodenoson has demonstrated a favourable safety profile
17 Apr 2025 According to a Can-Fite Biopharma media release, the company is actively enrolling patients in Israel in this trial
11 Nov 2024 Status changed from not yet recruiting to recruiting according to a Can-Fite Biopharma media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com